Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 1/2012

01-01-2012 | Gastrointestinal Oncology

Is Intraperitoneal Chemotherapy After Cytoreductive Surgery Efficient? Knowing Whether It Is or Not Appears Secondary!

Author: Dominique Elias, MD, PhD

Published in: Annals of Surgical Oncology | Issue 1/2012

Login to get access

Excerpt

The concept of treating peritoneal carcinomatosis (PC) with a curative intent by combining complete cytoreductive surgery (CCRS) resecting all visible disease plus hyperthermic intraperitoneal chemotherapy (HIPEC) or early postoperative intraperitoneal chemotherapy (EPIC) to eradicate the remaining nonvisible disease is logical and seems to be efficient. Described for the first time for 1 patient in 1980 by Spratt et al., it was extensively developed by Sugarbaker et al. during the following years.1,2 …
Literature
1.
Spratt JS, Adcock RA, Muskovin M, Sherril W, Mc Keown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40:256–60.PubMed
2.
Sugarbaker PH, Graves T, DeBruijn EA, Cunliffe WJ, Mullins RE, Hull WE, et al. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: Pharmacologic studies. Cancer Res. 1990;50:5790–4.PubMed
3.
Sugarbaker PH, Chang D. Result of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6:727–31.PubMedCrossRef
4.
Yan TD, Black D, Savady R, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2007;14:484–92.PubMedCrossRef
5.
Yan TD, Deraco M, Baratti D, Kusamara S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237–42.PubMedCrossRef
6.
Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.PubMedCrossRef
7.
da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer; J Am Coll Surg. 2006;203:878–86.PubMedCrossRef
8.
Elias D, Antoun S, Goharin A, El Otmany A, Puizillout JM, Lasser PH. Research on the best chemohyperthermia technique for treatment of peritoneal carcinomatosis after complete resection. Int J Surg Invest. 2000;1:431–9.
9.
Verwaal V, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FAN. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005;12:65–71.PubMedCrossRef
10.
Quenet F, Goéré D, Mehta S, Roca L, Dumont F, Essissen M, et al. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with and without irinotecan during HIPEC following cytoreductive surgery for colorectal carcinomatosis. Ann Surg. 2011 (in press).
Metadata
Title
Is Intraperitoneal Chemotherapy After Cytoreductive Surgery Efficient? Knowing Whether It Is or Not Appears Secondary!
Author
Dominique Elias, MD, PhD
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 1/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-011-1897-7

Other articles of this Issue 1/2012

Annals of Surgical Oncology 1/2012 Go to the issue

Gastrointestinal Oncology

Prognostic Significance of Lymph Node Metastases in Patients with High-Grade Appendiceal Cancer

Endocrine Tumors

Impact of Routine Unilateral Central Neck Dissection on Preablative and Postablative Stimulated Thyroglobulin Levels after Total Thyroidectomy in Papillary Thyroid Carcinoma

Breast Oncology

Changes in Psychosocial Functioning 1 Year After Mastectomy Alone, Delayed Breast Reconstruction, or Immediate Breast Reconstruction

Breast Oncology

A 10-Year Trend Analysis of Sentinel Lymph Node Frozen Section and Completion Axillary Dissection for Breast Cancer: Are These Procedures Becoming Obsolete?

Breast Oncology

Neoadjuvant Chemotherapy Is Associated with Improved Survival Compared with Adjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer Only after Complete Pathologic Response

Pancreatic Tumors

Survival after Resection of Pancreatic Adenocarcinoma: Results from a Single Institution over Three Decades